title: The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).
abstract: OBJECTIVE
  To offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments.
  
  
  METHODS
  The Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for metastatic CRPC based on available data and clinical experience.
  
  
  RESULTS
  A consensus was developed to address important questions on management of patients with metastatic CRPC.
  
  
  CONCLUSIONS
  In the absence of large-scale clinical trials, the Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action.
authors.affiliation: University of Colorado, Denver, CO. Electronic address: edc@edavidcrawford.com.
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.affiliation: Yale University, New Haven, CT.
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Petrylak
authors.affiliation: Carolina Urologic Research Center, Myrtle Beach, SC.
authors.forename: Neal
authors.initials: N
authors.lastname: Shore
authors.affiliation: Centre Hospitalier de L'Universite de Montreal, Montreal, QC, Canada.
authors.forename: Fred
authors.initials: F
authors.lastname: Saad
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Susan F
authors.initials: SF
authors.lastname: Slovin
authors.affiliation: Comprehensive Cancer Centers of Nevada, Las Vegas, NV.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
authors.affiliation: Medical University of South Carolina, Charleston, SC.
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Keane
authors.affiliation: Banner MD Anderson Cancer Center, Gilbert, AZ.
authors.forename: Phillip J
authors.initials: PJ
authors.lastname: Koo
authors.affiliation: Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
authors.forename: Leonard G
authors.initials: LG
authors.lastname: Gomella
authors.affiliation: Queen's University Belfast, Belfast, Northern Ireland, UK.
authors.forename: Joe M
authors.initials: JM
authors.lastname: O'Sullivan
authors.affiliation: Université Catholique de Louvain, Brussels, Belgium.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Tombal
authors.affiliation: Comprehensive Prostate Center, Nashville, TN.
authors.forename: Raoul S
authors.initials: RS
authors.lastname: Concepcion
authors.affiliation: Lancaster Urology, Lancaster, PA.
authors.forename: Paul
authors.initials: P
authors.lastname: Sieber
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, NY.
authors.forename: Nelson N
authors.initials: NN
authors.lastname: Stone
authors.affiliation: NRG Immunotherapy and Immunomodulation Committee, Scottsdale, AZ.
authors.forename: Steven E
authors.initials: SE
authors.lastname: Finkelstein
authors.affiliation: University of Washington, Seattle, WA.
authors.forename: Evan Y
authors.initials: EY
authors.lastname: Yu
mesh_terms: D000728:Androgens / Q000737:chemistry; D000736:Androstenes / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000494:pharmacology; D017410:Practice Guidelines as Topic; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D000736:Androstenes; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D011868:Radioisotopes; D010669:Phenylthiohydantoin; C540278:enzalutamide; C089740:abiraterone; D011883:Radium